Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.
Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.